Related Experiment Video

Updated: May 16, 2026

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

"Flagellated" cancer cells propel anti-tumor immunity

Johan Garaude1, J Magarian Blander

  • 1Institute for Research in Biotherapy; INSERM U1040; Montpellier, France.

Oncoimmunology
|November 20, 2012
PubMed

Insights

Introducing flagellin into tumor cells can overcome drawbacks in cancer therapy by enhancing tumor antigen presentation via dendritic cells (DCs) and triggering pattern recognition receptors (PRRs). This novel approach improves cancer treatment efficacy.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Cancer immunotherapies utilizing innate immune receptor agonists face significant challenges.
  • Existing strategies often fail to elicit a robust anti-tumor immune response.

Purpose of the Study:

  • To investigate the potential of flagellin, an innate immune receptor agonist, to enhance cancer therapy.
  • To explore flagellin's role in improving tumor antigen presentation and activating pattern recognition receptors (PRRs).

Main Methods:

  • Genetically modifying tumor cells to express flagellin.
  • Assessing the impact of flagellin on dendritic cell (DC) activation and antigen presentation.
  • Evaluating the simultaneous triggering of multiple PRRs within the tumor microenvironment.

Main Results:

  • Flagellin introduction into tumor cells promotes enhanced tumor antigen presentation by dendritic cells (DCs).
  • Simultaneous activation of two distinct types of pattern recognition receptors (PRRs) was observed.
  • Overcoming previously identified hurdles in innate immune-based cancer therapies.

Conclusions:

  • Intratumoral flagellin delivery represents a promising strategy to overcome limitations in current cancer immunotherapies.
  • This approach enhances anti-tumor immunity by improving antigen presentation and PRR activation.
  • Further research into flagellin-based cancer treatments is warranted.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle12:19

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle

Published on: June 7, 2024

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However, invadopodia can...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...